Overview

A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Status:
Not yet recruiting

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to identify the recommended dose for expansion (RDE) (and recommended schedule) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.

Phase:

Phase 1

Details

Lead Sponsor:

ADC Therapeutics S.A.

Treatments:

Gemcitabine